| A pharmacoeconomic evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study in the United Kingdom. | |
| | |
MedLine Citation:
|
PMID: 12648032 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To determine the short-term healthcare costs associated with intensive lipid lowering with atorvastatin initiated within 24-96 hours of the occurrence of acute coronary syndrome (ACS) in patients in the UK. METHODS: Patient-level clinical outcome data from the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial and standard cost data were used to compare the total expected 16-week cost per patient on atorvastatin 80 mg/day versus placebo. Clinical outcomes assessed included the following: death; cardiac arrest with resuscitation; nonfatal myocardial infarction; worsening angina pectoris with objective evidence of myocardial ischaemia requiring rehospitalisation; surgical or percutaneous coronary revascularisation; nonfatal stroke; hospitalisation for angina without objective evidence of myocardial ischaemia; and new or worsening congestive heart failure requiring rehospitalisation. All relevant direct medical costs from the perspective of the NHS were considered. RESULTS: The total expected cost was pound 784.05 per patient in the placebo cohort and pound 851.59 per patient in the atorvastatin cohort, resulting in an incremental cost of pound 67.54 per patient in the atorvastatin group. The cost per event avoided was pound 1762.04. A third of the cost of atorvastatin treatment was offset within 16 weeks by the cost savings resulting from the reduction in the number of events in the atorvastatin cohort compared with the placebo cohort. CONCLUSION: The clinical benefits of short-term intensive atorvastatin treatment administered after ACS is attainable through a marginal increase in 'upfront' costs. |
| | |
Authors:
|
Nigel Buller; David Gillen; Roman Casciano; John Doyle; Koo Wilson |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: PharmacoEconomics Volume: 21 Suppl 1 ISSN: 1170-7690 ISO Abbreviation: Pharmacoeconomics Publication Date: 2003 |
Date Detail:
|
Created Date: 2003-03-21 Completed Date: 2003-06-05 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 9212404 Medline TA: Pharmacoeconomics Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 25-32 Citation Subset: T |
Affiliation:
|
Department of Cardiology, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anticholesteremic Agents
/
economics*,
therapeutic use* Cholesterol / blood Cohort Studies Cost-Benefit Analysis Double-Blind Method Endpoint Determination Great Britain Health Care Costs Heptanoic Acids / economics*, therapeutic use* Hospitalization Humans Hypercholesterolemia / blood, complications, drug therapy* Myocardial Ischemia / drug therapy*, etiology, prevention & control* Pyrroles / economics*, therapeutic use* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Heptanoic Acids; 0/Pyrroles; 110862-48-1/atorvastatin; 57-88-5/Cholesterol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Next Document: Financial and health costs of uncontrolled blood pressure in the United Kingdom.